NCT01644513已完成不适用
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal Anti-VEGF Injections (Bevacizumab or Ranibizumab) to Evaluate the Association Between Genetic Load and Response to Therapy/Treatment Burden
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 196
- 试验地点
- 1
研究概览
简要总结
Patients with AMD who are being or have been treated with eye injections of drugs known as anti-VEGF agents with either good or poor response will have DNA collected with check swabs for analysis.
详细描述
The study is designed as a single-center, observational case control evaluation to compare the genetic profiles of two groups of patients categorized according to anti-VEGF treatment response as either "positive" or "suboptimal" responders following treatment with either bevacizumab or ranibizumab anti-VEGF agents. Positive and suboptimal responders will be compared to determine if genetic variant distribution or total genetic load is associated with anti-VEGF treatment response.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is male or female 55 years of age and older
- •Subject is self-reported as non-Hispanic Caucasian
- •Subject provides a signed and dated informed consent
- •Subject agrees to provide two buccal swabs in accordance with this protocol
- •Diagnosis of CNV secondary to AMD in at least one eye
- •Subject satisfies one of the following:
- •Has received at least one injection of anti-VEGF therapy (bevacizumab or ranibizumab) with no evidence of residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection; or
- •Has received three or more injections in last six months with residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection, has not shown complete resolution of fluid following any injection in last 6 months, and shows leakage on FA or ICG imaging at some time during last 12 months.
排除标准
- •Previous sample donation under this protocol
- •Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD loss such as high myopia, retinal dystrophies, central serous retinopathy, vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of
- •Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate imaging of the posterior segment.
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular DiseasesPolypoidal Choroidal VasculopathyConberceptPharmacogenomicPathological MyopiaAge-Related Macular DegenerationNCT03128463Xun Xu5,000
已完成
不适用
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)Age-Related Macular DegenerationNCT02762188Brugmann University Hospital501
已完成
不适用
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)Age-related Macular Degeneration (AMD)NCT05110209Novartis Pharmaceuticals331,541
进行中（未招募）
不适用
Ocular, Vascular, and Genetic Findings in AMD PatientsAge-Related Macular DegenerationNCT06015633OcuDyne, Inc.50
Unknown
4 期
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMDMacular DegenerationNCT01213667University of Cologne110